Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132186) titled 'ALT001 Phase II Dose-Finding Clinical Study for the Treatment of Amyotrophic Lateral Sclerosis' on Sept. 10.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Beijing Tiantan Hospital, Capital Medical University
Condition:
Amyotrophic Lateral Sclerosis
Intervention:
Experimental group1:ALT001 1.0µg/kg
Experimental group2:ALT001 2.0µg/kg
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-10
Target Sample Size: Experimental group1:50;Experimental group2:50;Placebo group:50;
Countries of Recruitment:
China
To know more, visit https://www.c...